NCT07903415
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 4 words
- Start date changed from estimate of Oct 29, 2026 to Nov 5, 2026
- Minor Study sites: 2 to 4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Adverse Events (AEs)
Timeframe: Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first)
Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM)
Timeframe: From first dose through completion of Part 1, an average of 1 year
Part 2: Recommended Monotherapy Dose for Further Development
Timeframe: From first dose through completion of Part 2, an average of 2 years
Secondary (8)
Objective Response Rate (ORR)
Duration of Response (DOR)
Progression Free Survival (PFS)
Overall Survival (OS)
Maximum Observed Serum Concentration (Cmax)
Show 3 moreShow less
Area under the concentration-time curve (AUC)
Time to Maximum Observed Serum Concentration (Tmax)
Number of Participants With Anti-drug Antibody (ADA) against PF-08098488
Arms and interventions
Part 1 Dose EscalationExperimental
Different groups of participants will receive different doses and/or schedules of the study drug
Part 2 Dose ExpansionExperimental
Participants in tumor-specific groups will receive 1 dosing regimen deemed to be safe in Part 1
Part 2 Dose OptimizationExperimental
Participants will be assigned to one of two dosing regimens deemed to be safe in Part 1
Drugs: PF-08098488
Sites
4 sites in 1 country